Literature DB >> 30944166

Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Charles R Esther1,2, Marianne S Muhlebach3,2, Camille Ehre3,2, David B Hill2,4, Matthew C Wolfgang2, Mehmet Kesimer2, Kathryn A Ramsey2,5, Matthew R Markovetz2, Ian C Garbarine2, M Gregory Forest6, Ian Seim6, Bryan Zorn2, Cameron B Morrison2, Martial F Delion2, William R Thelin7, Diane Villalon7, Juan R Sabater8, Lidija Turkovic5, Sarath Ranganathan9, Stephen M Stick5,10,11, Richard C Boucher2.   

Abstract

Although destructive airway disease is evident in young children with cystic fibrosis (CF), little is known about the nature of the early CF lung environment triggering the disease. To elucidate early CF pulmonary pathophysiology, we performed mucus, inflammation, metabolomic, and microbiome analyses on bronchoalveolar lavage fluid (BALF) from 46 preschool children with CF enrolled in the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program and 16 non-CF disease controls. Total airway mucins were elevated in CF compared to non-CF BALF irrespective of infection, and higher densities of mucus flakes containing mucin 5B and mucin 5AC were observed in samples from CF patients. Total mucins and mucus flakes correlated with inflammation, hypoxia, and oxidative stress. Many CF BALFs appeared sterile by culture and molecular analyses, whereas other samples exhibiting bacterial taxa associated with the oral cavity. Children without computed tomography-defined structural lung disease exhibited elevated BALF mucus flakes and neutrophils, but little/no bacterial infection. Although CF mucus flakes appeared "permanent" because they did not dissolve in dilute BALF matrix, they could be solubilized by a previously unidentified reducing agent (P2062), but not N-acetylcysteine or deoxyribonuclease. These findings indicate that early CF lung disease is characterized by an increased mucus burden and inflammatory markers without infection or structural lung disease and suggest that mucolytic and anti-inflammatory agents should be explored as preventive therapy.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2019        PMID: 30944166      PMCID: PMC6566903          DOI: 10.1126/scitranslmed.aav3488

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  71 in total

1.  Concordance between upper and lower airway microbiota in infants with cystic fibrosis.

Authors:  Sabine M P J Prevaes; Wouter A A de Steenhuijsen Piters; Karin M de Winter-de Groot; Hettie M Janssens; Gerdien A Tramper-Stranders; Mei Ling J N Chu; Harm A Tiddens; Mireille van Westreenen; Cornelis K van der Ent; Elisabeth A M Sanders; Debby Bogaert
Journal:  Eur Respir J       Date:  2017-03-29       Impact factor: 16.671

2.  Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.

Authors:  Nicholas W Keiser; Susan E Birket; Idil A Evans; Scott R Tyler; Adrianne K Crooke; Xingshen Sun; Weihong Zhou; Joseph R Nellis; Elizabeth K Stroebele; Kengyeh K Chu; Guillermo J Tearney; Mark J Stevens; J Kirk Harris; Steven M Rowe; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2015-06       Impact factor: 6.914

Review 3.  Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.

Authors:  Richard C Boucher
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

4.  Hyposecretion of fluid from tracheal submucosal glands of CFTR-deficient pigs.

Authors:  Nam Soo Joo; Hyung-Ju Cho; Monal Khansaheb; Jeffrey J Wine
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

Review 5.  Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis.

Authors:  Paul M Quinton
Journal:  Lancet       Date:  2008-08-02       Impact factor: 79.321

6.  Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals.

Authors:  Christine M Bassis; John R Erb-Downward; Robert P Dickson; Christine M Freeman; Thomas M Schmidt; Vincent B Young; James M Beck; Jeffrey L Curtis; Gary B Huffnagle
Journal:  MBio       Date:  2015-03-03       Impact factor: 7.867

7.  Airway surface liquid pH is not acidic in children with cystic fibrosis.

Authors:  André Schultz; Ramaa Puvvadi; Sergey M Borisov; Nicole C Shaw; Ingo Klimant; Luke J Berry; Samuel T Montgomery; Thien Nguyen; Silvia M Kreda; Anthony Kicic; Peter B Noble; Brian Button; Stephen M Stick
Journal:  Nat Commun       Date:  2017-11-10       Impact factor: 14.919

8.  A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.

Authors:  David B Hill; Paula A Vasquez; John Mellnik; Scott A McKinley; Aaron Vose; Frank Mu; Ashley G Henderson; Scott H Donaldson; Neil E Alexis; Richard C Boucher; M Gregory Forest
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

9.  Aspirated bile: a major host trigger modulating respiratory pathogen colonisation in cystic fibrosis patients.

Authors:  F J Reen; D F Woods; M J Mooij; M N Chróinín; D Mullane; L Zhou; J Quille; D Fitzpatrick; J D Glennon; G P McGlacken; C Adams; F O'Gara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-11       Impact factor: 3.267

10.  The normal trachea is cleaned by MUC5B mucin bundles from the submucosal glands coated with the MUC5AC mucin.

Authors:  Anna Ermund; Lauren N Meiss; Ana M Rodriguez-Pineiro; Andrea Bähr; Harriet E Nilsson; Sergio Trillo-Muyo; Caroline Ridley; David J Thornton; Jeffrey J Wine; Hans Hebert; Nikolai Klymiuk; Gunnar C Hansson
Journal:  Biochem Biophys Res Commun       Date:  2017-08-30       Impact factor: 3.575

View more
  45 in total

1.  Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways.

Authors:  Yan Shin J Liao; Shin Ping Kuan; Maria V Guevara; Emily N Collins; Kalina R Atanasova; Joshua S Dadural; Kevin Vogt; Veronica Schurmann; Laura Bravo; Eda Eken; Mariana Sponchiado; Leah R Reznikov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-11       Impact factor: 5.464

2.  Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models.

Authors:  Kaitlyn R Rouillard; David B Hill; Mark H Schoenfisch
Journal:  J Cyst Fibros       Date:  2020-03-21       Impact factor: 5.482

Review 3.  Mucus, mucins, and cystic fibrosis.

Authors:  Cameron Bradley Morrison; Matthew Raymond Markovetz; Camille Ehre
Journal:  Pediatr Pulmonol       Date:  2019-11

Review 4.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Authors:  Marcus A Mall; Nicole Mayer-Hamblett; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

5.  Revealing the molecular signaling pathways of mucus stasis in cystic fibrosis.

Authors:  Susan E Birket; Steven M Rowe
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 6.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

7.  Induction of ciliary orientation by matrix patterning and characterization of mucociliary transport.

Authors:  Patrick R Sears; Ximena M Bustamante-Marin; Henry Gong; Matthew R Markovetz; Richard Superfine; David B Hill; Lawrence E Ostrowski
Journal:  Biophys J       Date:  2021-03-09       Impact factor: 4.033

8.  Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis.

Authors:  Deirdre Gilpin; Lucas R Hoffman; Agathe Ceppe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2021-06-06       Impact factor: 5.482

9.  Membrane-bound mucins of the airway mucosal surfaces are densely decorated with keratan sulfate: revisiting their role in the Lung's innate defense.

Authors:  Jerome Carpenter; Mehmet Kesimer
Journal:  Glycobiology       Date:  2021-05-03       Impact factor: 4.313

10.  Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.

Authors:  Cameron B Morrison; Kendall M Shaffer; Kenza C Araba; Matthew R Markovetz; Jason A Wykoff; Nancy L Quinney; Shuyu Hao; Martial F Delion; Alexis L Flen; Lisa C Morton; Jimmy Liao; David B Hill; Mitchell L Drumm; Wanda K O'Neal; Mehmet Kesimer; Martina Gentzsch; Camille Ehre
Journal:  Eur Respir J       Date:  2022-02-03       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.